CD34 and angina pectoris: The phase I double-blinded, placebo-controlled trial included 24 patients with CCS class III (three) or IV (four) angina who were receiving optimal medical care, and it showed initial safety, as well as clinical improvement in the CD34+, treated individuals [8].